wherein R is H, a methyl group, an ethyl group, a n-propyl group, an iso-propyl group, or a n-butyl group； and R1 is H, a 4′-methyl group, a 4′-OH, a 4′-OMe group, a 2′,3′-C2H4 group, a； 3′,4′-C2H4 group, a 3′,4′-diF, a 3′,4′,5′-triF, or a 4′-OCF3； and optionally including a salt or a hydrate of said compound, and further provides a pharmaceutical composition comprising the compound of Formula I and one or more acceptable pharmaceutical carriers. A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutical composition comprising a compound of Formula I and one or more acceptable pharmaceutical carriers to the patient is disclosed.
